Vaccines against botulism

Current Opinion in Microbiology

Volumn 15, Issue 3, 2012, Pages 317-324

  Karalewitz, Andrew P A ^a   Barbieri, Joseph T ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; BOTULINUM TOXIN F; DIPHTHERIA TOXIN; SNARE PROTEIN; SUBUNIT VACCINE; TETANUS TOXIN;

BOTULISM; CLOSTRIDIUM BOTULINUM; DIPHTHERIA; ESCHERICHIA COLI; HUMAN; IMMUNIZATION; NERVE CELL; NEUROTROPISM; NONHUMAN; PICHIA PASTORIS; PROTEIN CLEAVAGE; REVIEW; TETANUS; VACCINE PRODUCTION;

AMINO ACID SEQUENCE; ANIMALS; BACTERIAL VACCINES; BOTULINUM TOXINS; BOTULISM; CLOSTRIDIUM BOTULINUM; HUMANS; MICE; MOLECULAR SEQUENCE DATA; SEQUENCE ALIGNMENT; VACCINES, SUBUNIT;

EID: 84864050116     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2012.05.009     Document Type: Review

References (72)

1. Poulain B., Popoff M.R., Molgo J. How do the botulinum neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. Botulinum J 2008, 1:14-87.
2. Aoki K.R., Smith L.A., Atassi M.Z. Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition. Crit Rev Immunol 2010, 30:167-187.
3. Dertzbaugh M.T., West M.W. Mapping of protective and cross-reactive domains of the type a neurotoxin of clostridium botulinum. Vaccine 1996, 14:1538-1544.
4. Burgen A.S.V., Dickens F., Zatman L.J. The action of botulinum toxin on the neuro-muscular junction. J Physiol 1949, 109:10-24.
5. Torda C., Wolff H.G. On the mechanism of paralysis resulting from toxin of clostridium botulinum. J Pharmacol Exp Ther 1947, 89:320-324.
6. Sudhof T.C. The synaptic vesicle cycle. Annu Rev Neurosci 2004, 27:509-547.
7. DasGupta B.R., Sugiyama H. A common subunit structure in clostridium botulinum type a, b and e toxins. Biochem Biophys Res Commun 1972, 48:108-112.
8. Simpson L.L. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 1981, 33:155-188.
9. Lacy D.B., Tepp W., Cohen A.C., DasGupta B.R., Stevens R.C. Crystal structure of botulinum neurotoxin type a and implications for toxicity. Nat Struct Biol 1998, 5:898-902.
10. Swaminathan S., Eswaramoorthy S. Structural analysis of the catalytic and binding sites of clostridium botulinum neurotoxin b. Nat Struct Mol Biol 2000, 7:693-699.
11. Montal M. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem 2010, 79:591-617.
12. Fischer A., Montal M. Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc Natl Acad Sci USA 2007, 104:10447-10452.
13. Fischer A., Nakai Y., Eubanks L.M., Clancy C.M., Tepp W.H., Pellett S., Dickerson T.J., Johnson E.A., Janda K.D., Montal M. Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci USA 2009, 106:1330-1335.
14. Varki A., Cummings R., Esko J.D., Freeze H.H., Stanley P., Bertozzi C., Hart G.W., Etzler M.E. Essential of Glycobiology 2009, Cold Spring Harbor Laboratory Press, New York.
15. Rummel A., Mahrhold S., Bigalke H., Binz T. Exchange of the h(cc) domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin. FEBS J 2011, 278:4506-4515.
16. Thomas B., Andreas R. Cell entry strategy of clostridial neurotoxins. J Neurochem 2009, 109:1584-1595.
17. Baldwin M.R., Kim J.-J.P., Barbieri J.T. Botulinum neurotoxin b-host receptor recognition: it takes two receptors to tango. Nat Struct Mol Biol 2007, 14:9-10.
18. Nishiki T., Kamata Y., Nemoto Y., Omori A., Ito T., Takahashi M., Kozaki S. Identification of protein receptor for clostridium botulinum type b neurotoxin in rat brain synaptosomes. J Biol Chem 1994, 269:10498-10503.
19. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., Chapman E.R. Sv2 is the protein receptor for botulinum neurotoxin a. Science 2006, 312:592-596.
20. Dong M., Richards D.A., Goodnough M.C., Tepp W.H., Johnson E.A., Chapman E.R. Synaptotagmins i and ii mediate entry of botulinum neurotoxin b into cells. J Cell Biol 2003, 162:1293-1303.
21. Dong M., Liu H., Tepp W.H., Johnson E.A., Janz R., Chapman E.R. Glycosylated sv2a and sv2b mediate the entry of botulinum neurotoxin e into neurons. Mol Biol Cell 2008, 19:5226-5237.
22. Fu Z., Chen C., Barbieri J.T., Kim J.-J.P., Baldwin M.R. Glycosylated sv2 and gangliosides as dual receptors for botulinum neurotoxin serotype f. Biochemistry 2009, 48:5631-5641.
23. Rummel A., Hafner K., Mahrhold S., Darashchonak N., Holt M., Jahn R., Beermann S., Karnath T., Bigalke H., Binz T. Botulinum neurotoxins c, e and f bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin f utilising the three isoforms of sv2 as second receptor. J Neurochem 2009, 110:1942-1954.
24. Koriazova L.K., Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Mol Biol 2003, 10:13-18.
25. Chen S., Barbieri J.T. Association of botulinum neurotoxin serotype a light chain with plasma membrane-bound snap-25. J Biol Chem 2011, 286:15067-15072.
26. Schiavo G.P., Benfenati F., Poulain B., Rossetto O., de Laureto P.P., DasGupta B.R., Montecucco C. Tetanus and botulinum-b neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992, 359:832-835.
27. Yowler B., Schengrund C.-L. Glycosphingolipids-sweets for botulinum neurotoxin. Glycoconj J 2004, 21:287-293.
28. Emsley P., Fotinou C., Black I., Fairweather N.F., Charles I.G., Watts C., Hewitt E., Isaacs N.W. The structures of the hc fragment of tetanus toxin with carbohydrate subunit complexes provide insight into ganglioside binding. J Biol Chem 2000, 275:8889-8894.
29. Shapiro R.E., Specht C.D., Collins B.E., Woods A.S., Cotter R.J., Schnaar R.L. Identification of a ganglioside recognition domain of tetanus toxin using a novel ganglioside photoaffinity ligand. J Biol Chem 1997, 272:30380-30386.
30. Rummel A., Mahrhold S., Bigalke H., Binz T. The hcc-domain of botulinum neurotoxins a and b exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol 2004, 51:631-643.
31. Stenmark P., Dupuy J., Imamura A., Kiso M., Stevens R.C. Crystal structure of botulinum neurotoxin type a in complex with the cell surface co-receptor gt1b "insight into the toxin" neuron interaction. PLoS Pathog 2008, 4:e1000129.
32. Chai Q., Arndt J.W., Dong M., Tepp W.H., Johnson E.A., Chapman E.R., Stevens R.C. Structural basis of cell surface receptor recognition by botulinum neurotoxin b. Nature 2006, 444:1096-1100.
33. Jin R., Rummel A., Binz T., Brunger A.T. Botulinum neurotoxin b recognizes its protein receptor with high affinity and specificity. Nature 2006, 444:1092-1095.
34. Smith L.A. Botulism and vaccines for its prevention. Vaccine 2009, 27(Suppl. 4):D33-D39.
35. Graham R., Thorp F. The effect of formalin on botulinum toxins a, b and c. J Immunol 1929, 16:391-401.
36. Nigg C., Hottle G.A., Coriell L.L., Rosenwald A.S., Beveridge G.W. Studies on botulinum toxoid, types a and b. J Immunol 1947, 55:245-254.
37. Reames H.R., Kadull P.J., Housewright R.D., Wilson J.B. Studies on botulinum toxoids, types A and B; immunization of man. J Immunology 1947, 55:309-324.
38. Duff J.T., Wright G.G., Klerer J., Moore D.E., Bibler R.H. Studies on immunity to toxins of clostridium botulinum i. A. J Bacteriol 1957, 73:42-47.
39. Wright G.G., Duff J.T., Fiock M.A., Devlin H.B., Soderstrom R.L. Studies on immunity to toxins of clostridium botulinum. J Immunol 1960, 84:384-389.
40. Fiock M.A., Cardella M.A., Gearinger N.F. Studies on immunity to toxins of clostridium botulinum. Ix. Immunologic response of man to purified pentavalent abcde botulinum toxiod. J Immunol 1963, 90:697-702.
41. Fairweather N.F., Lyness V.A., Maskell D.J. Immunization of mice against tetanus with fragments of tetanus toxin synthesized in escherichia coli. Infect Immun 1987, 55:2541-2545.
42. Clayton M.A., Clayton J.M., Brown D.R., Middlebrook J.L. Protective vaccination with a recombinant fragment of clostridium botulinum neurotoxin serotype a expressed from a synthetic gene in escherichia coli. Infect Immun 1995, 63:2738-2742.
43. Baldwin M.R., Tepp W.H., Przedpelski A., Pier C.L., Bradshaw M., Johnson E.A., Barbieri J.T. Subunit vaccine against the seven serotypes of botulism. Infect Immun 2008, 76:1314-1318.
44. Smith L.A. Development of recombinant vaccines for botulinum neurotoxin. Toxicon 1998, 36:1539-1548.
45. Byrne M.P., Smith T.J., Montgomery V.A., Smith L.A. Purification, potency, and efficacy of the botulinum neurotoxin type a binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 1998, 66:4817-4822.
46. Park J.-B., Simpson L.L. Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infect Immun 2003, 71:1147-1154.
47. Baldwin M.R., Tepp W.H., Pier C.L., Bradshaw M., Ho M., Wilson B.A., Fritz R.B., Johnson E.A., Barbieri J.T. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes a and e. Infect Immun 2005, 73:6998-7005.
48. Tavallaie M., Chenal A., Gillet D., Pereira Y., Manich M., Gibert M., Raffestin S., Popoff M.R., Marvaud J.C. Interaction between the two subdomains of the c-terminal part of the botulinum neurotoxin a is essential for the generation of protective antibodies. FEBS Lett 2004, 572:299-306.
49. Pier C.L., Tepp W.H., Bradshaw M., Johnson E.A., Barbieri J.T., Baldwin M.R. Recombinant holotoxoid vaccine against botulism. Infect Immun 2008, 76:437-442.
50. Webb R.P., Smith T.J., Wright P., Brown J., Smith L.A. Production of catalytically inactive bont/a1 holoprotein and comparison with bont/a1 subunit vaccines against toxin subtypes a1, a2, and a3. Vaccine 2009, 27:4490-4497.
51. Atassi M.Z., Dolimbek B.Z., Jankovic J., Steward L.E., Aoki K.R. Regions of botulinum neurotoxin a light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology 2011, 216:782-792.
52. Atassi M.Z., Jankovic J., Steward L.E., Aoki K.R., Dolimbek B.Z. Molecular immune recognition of botulinum neurotoxin b. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire bont/b molecule. Immunobiology 2012, 217:17-27.
53. Gelzleichter T.R., Myers M.A., Menton R.G., Niemuth N.A., Matthews M.C., Langford M.J. Protection against botulinum toxins provided by passive immunization with botulinum human immune globulin: evaluation using an inhalation model. J Appl Toxicol 1999, 19(Suppl. 1):S35-S38.
54. Shearer J.D., Vassar M.L., Swiderski W., Metcalfe K., Niemuth N., Henderson I. Botulinum neurotoxin neutralizing activity of immune globulin (ig) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rbv a/b). Vaccine 2010, 28:7313-7318.
55. Nowakowski A., Wang C., Powers D.B., Amersdorfer P., Smith T.J., Montgomery V.A., Sheridan R., Blake R., Smith L.A., Marks J.D. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA 2002, 99:11346-11350.
56. Cheng L.W., Stanker L.H., Henderson T.D., Lou J., Marks J.D. Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun 2009, 77:4305-4313.
57. Sepulveda J., Mukherjee J., Tzipori S., Simpson L.L., Shoemaker C.B. Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents. Infect Immun 2010, 78:756-763.
58. Mukherjee J., Tremblay J.M., Leysath C.E., Ofori K., Baldwin K., Feng X., Bedenice D., Webb R.P., Wright P.M., Smith L.A., et al. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS ONE 2012, 7:e29941.
59. Hill K.K., Smith T.J., Helma C.H., Ticknor L.O., Foley B.T., Svensson R.T., Brown J.L., Johnson E.A., Smith L.A., Okinaka R.T., et al. Genetic diversity among botulinum neurotoxin-producing clostridial strains. J Bacteriol 2007, 189:818-832.
60. Jacobson M.J., Lin G., Tepp W., Dupuy J., Stenmark P., Stevens R.C., Johnson E.A. Purification, modeling, and analysis of botulinum neurotoxin subtype a5 (bont/a5) from clostridium botulinum strain a661222. Appl Environ Microbiol 2011, 77:4217-4222.
61. Raphael B.H., Choudoir M.J., Lúquez C., Fernández R., Maslanka S.E. Sequence diversity of genes encoding botulinum neurotoxin type f. Appl Environ Microbiol 2010, 76:4805-4812.
62. Pier C.L., Chen C., Tepp W.H., Lin G., Janda K.D., Barbieri J.T., Pellett S., Johnson E.A. Botulinum neurotoxin subtype a2 enters neuronal cells faster than subtype a1. FEBS Lett 2011, 585:199-206.
63. Henkel J.S., Jacobson M., Tepp W., Pier C., Johnson E.A., Barbieri J.T. Catalytic properties of botulinum neurotoxin subtypes a3 and a4. Biochemistry 2009, 48:2522-2528.
64. Arndt J.W., Jacobson M.J., Abola E.E., Forsyth C.M., Tepp W.H., Marks J.D., Johnson E.A., Stevens R.C. A structural perspective of the sequence variability within botulinum neurotoxin subtypes a1-a4. J Mol Biol 2006, 362:733-742.
65. Henkel J.S., Tepp W.H., Przedpelski A., Fritz R.B., Johnson E.A., Barbieri J.T. Subunit vaccine efficacy against botulinum neurotoxin subtypes. Vaccine 2011, 29:7688-7695.
66. Eklund M.W., Poysky F.T., Reed S.M. Bacteriophage and the toxigenicity of clostridium botulinum type d. Nat New Biol 1972, 235:16-17.
67. Eklund M.W., Poysky F.T., Reed S.M., Smith C.A. Bacteriophage and the toxigenicity of clostridium botulinum type c. Science 1971, 172:480-482.
68. Moriishi K., Syuto B., Kubo S., Oguma K. Molecular diversity of neurotoxins from clostridium botulinum type d strains. Infect Immun 1989, 57:2886-2891.
69. Moriishi K., Koura M., Abe N., Fujii N., Fujinaga Y., Inoue K., Ogumad K. Mosaic structures of neurotoxins produced from clostridium botulinum types c and d organisms. Biochim Biophys Acta 1996, 1307:123-126.
70. Webb R.P., Smith T.J., Wright P.M., Montgomery V.A., Meagher M.M., Smith L.A. Protection with recombinant clostridium botulinum c1 and d binding domain subunit (hc) vaccines against c and d neurotoxins. Vaccine 2007, 25:4273-4282.
71. Karalewitz A.P., Kroken A.R., Fu Z., Baldwin M.R., Kim J.J., Barbieri J.T. Identification of a unique ganglioside binding loop within botulinum neurotoxins c and d-sa. Biochemistry 2010, 49:8117-8126.
72. Scarselli M., Arico B., Brunelli B., Savino S., Di Marcello F., Palumbo E., Veggi D., Ciucchi L., Cartocci E., Bottomley M.J., et al. Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med 2011, 3:91ra62.